Skip to main content
AMLX
NASDAQ Life Sciences

Amylyx Pharmaceuticals Reports Q1 2026 Results, Advances Multiple Clinical Programs

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$16.51
Mkt Cap
$1.775B
52W Low
$4.2
52W High
$18.605
52W Position info
293% above low
Off High info
11% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

AMLX has more than doubled off its 52-week low of $4.2.

Summary

Amylyx Pharmaceuticals reported Q1 2026 financial results with an increased net loss but highlighted substantial progress in its clinical pipeline, including Phase 3 enrollment completion for avexitide and positive Phase 2 data for AMX0035, while maintaining its cash runway into 2028.


Key Events · Product Development and Regulatory · AMLX

  • Q1 2026 Financial Results

    Reported a net loss of $41.284 million for the three months ended March 31, 2026, an increase from $35.907 million in the prior year period. Research and development expenses increased by 25% to $27.610 million, primarily driven by avexitide and new programs, partially offset by the discontinuation of AMX0035 for PSP.

  • Avexitide Phase 3 Enrollment Completed

    Enrollment for the pivotal Phase 3 LUCIDITY clinical trial evaluating avexitide in post-bariatric hypoglycemia (PBH) was completed in March 2026. Topline data is anticipated in the third quarter of 2026, with a potential commercial launch in 2027 if approved. An Expanded Access Program (EAP) for avexitide in PBH was initiated in May 2026.

  • AMX0035 Shows Sustained Positive Phase 2 Data

    Positive Week 48 data from the Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome demonstrated continued and sustained improvement in pancreatic beta cell function, glycemic control, and visual acuity. Discussions with the FDA for a Phase 3 trial are ongoing.

  • Pipeline Expansion with AMX0318 and AMX0114 Progress

    AMX0318 was selected as a development candidate for PBH and other rare diseases in January 2026, triggering a $4 million milestone payment to Gubra. IND-enabling studies are underway, targeting an IND in 2027. Enrollment for Cohort 2 of the Phase 1 LUMINA trial for AMX0114 in ALS was completed in March 2026, with Cohort 1 biomarker data expected in June 2026.


Analysis · AMLX · Life Sciences

Amylyx Pharmaceuticals reported an increased net loss for Q1 2026 but demonstrated significant progress across its clinical pipeline, maintaining a cash runway into 2028. Key advancements include the completion of enrollment for the pivotal Phase 3 LUCIDITY trial for avexitide in PBH, with topline data expected in Q3 2026, and positive long-term data from the Phase 2 HELIOS trial for AMX0035 in Wolfram syndrome. The company also advanced AMX0114 in ALS and selected AMX0318 as a new development candidate, indicating a robust and progressing pipeline. The resolution of a class action lawsuit for $6.5 million, largely covered by insurance, removes a minor legal overhang.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AMLX was trading at $16.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $4.20 to $18.61. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AMLX - Latest Insights

AMLX
Nov 05, 2026, 7:04 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $30.00
Real-time Price: $26.63 info
Change: -$3.37 (-11%) info
Market Cap: $3.422B info
AMLX
Sep 08, 2026, 4:54 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $33.88
Real-time Price: $26.63 info
Change: -$7.25 (-21%) info
Market Cap: $3.422B info
AMLX
Aug 20, 2026, 5:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $39.71
Real-time Price: $26.63 info
Change: -$13.08 (-33%) info
Market Cap: $3.422B info
AMLX
Aug 20, 2026, 5:27 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $39.71
Real-time Price: $26.63 info
Change: -$13.08 (-33%) info
Market Cap: $3.422B info
AMLX
Aug 19, 2026, 11:06 PM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $38.45
Real-time Price: $26.63 info
Change: -$11.82 (-31%) info
Market Cap: $3.422B info